Edwards Lifesciences (EW) PT Raised to $130 at Stifel; Reiterates Buy

Edwards Lifesciences (EW) PT Raised to $155 at Canaccord Genuity on 2Q Beat; 'Keep Buying... Upside to Raised Guidance in the Cards'

Canaccord Genuity raised its price target on Edwards Lifesciences (NYSE: EW) to $155.00 (from $150.00) while maintaining a Buy rating, following the company's second quarter earnings announcement.

Analyst Jason Mills notes the company delivered a second quarter earnings per share and revenue results above consensus projections... More

Edwards Lifesciences (EW) PT Raised to $132 at Jefferies

Jefferies raised its price target on Edwards Lifesciences (NYSE: EW) to $132.00 (from $115.00) while maintaining a Buy rating following the company's 2Q. EW put up another impressive TAVR Q with +23.3% underlying y/y growth and +7% growth sequentially. After adding back $22.5mn of German inventory... More

Edwards Lifesciences (EW): TAVR Outperformance Drives A PT Increase - Cowen

Cowen analyst, Joshua Jennings, reiterated his Outperform rating on shares of Edwards Lifesciences (NYSE: EW) and raised his price target to $135 after S3s strong sequential U.S. growth, international TAVR outperformance, outsized margin results and a ~$0.07 EPS beat (adjusting for the... More

After-Hours Movers 07/26: (AXTI) (NTGR) (FB) Higher; (CUR) (CYH) (BWLD) Lower (more...)

After-Hours Movers

Neuralstem, Inc. (Nasdaq: CUR) 18.6% LOWER; announced it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock and warrants to purchase shares of its common stock. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Community Health Systems (NYSE: CYH) 14% LOWER; providing a preliminary update to its 2017 annual guidance... More

Edwards Lifesciences (EW) Tops Q2 EPS by 20c; Raises Outlook

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $1.08, $0.20 better than the analyst estimate of $0.88. Revenue for the quarter came in at $842 million versus the consensus estimate of $840.06 million.

GUIDANCE:

Edwards Lifesciences sees FY2017 EPS of $3.65-$3.85, versus the consensus of... More